JINYU(SH:600201)2020-10-22 16:00Financial Performance - Operating income rose by 30.65% to CNY 1,107,743,155.19 for the first nine months of the year[17] - Net profit attributable to shareholders increased by 19.03% to CNY 295,732,932.28 year-on-year[17] - Total profit increased by RMB 83.39 million, up 31.30%, attributed to the recovery in the pig farming industry and the promotion of a combination immunization marketing plan[30] - Total operating revenue for Q3 2020 reached ¥483.39 million, a 43.6% increase from ¥336.61 million in Q3 2019[54] - Net profit attributable to shareholders for Q3 2020 was ¥113.29 million, compared to ¥78.46 million in Q3 2019, reflecting a 44.4% increase[61] - The total comprehensive income for the first three quarters of 2020 was ¥120,373,646.13, compared to ¥85,852,201.51 in the same period of 2019, representing an increase of about 40.2%[63] Assets and Liabilities - Total assets increased by 9.77% to CNY 6,131,452,234.03 compared to the end of the previous year[17] - Total liabilities reached $1.03 billion, up from $716.78 million, which is an increase of approximately 43.3%[44] - Shareholders' equity rose to $5.10 billion, compared to $4.87 billion, reflecting an increase of about 4.5%[44] - The company reported a total of $1.51 billion in current assets, slightly down from $1.53 billion, a decrease of about 0.5%[49] - The company’s total liabilities and shareholders' equity reached ¥4.38 billion, compared to ¥4.36 billion in the previous quarter[54] Cash Flow - Net cash flow from operating activities surged by 222.10% to CNY 403,880,298.08 for the first nine months[17] - Cash received from operating activities increased by RMB 149.83 million, a rise of 193.03%, mainly due to government subsidies received[31] - The net cash flow from operating activities was CNY 403,880,298.08, a significant increase from CNY 125,391,321.62 in the previous period, reflecting a strong operational performance[72] - Total cash inflow from investment activities amounted to CNY 539,714,796.79, down from CNY 1,528,665,904.04, indicating a decrease in investment returns[72] - Cash outflow from financing activities totaled CNY 106,731,676.95, a decrease from CNY 767,398,631.26, suggesting reduced financing costs[74] Shareholder Information - The total number of shareholders reached 36,158 by the end of the reporting period[21] - The largest shareholder, Hong Kong Central Clearing Limited, holds 16.09% of shares[21] Research and Development - Research and development expenses increased by RMB 24.75 million, a rise of 41.10%, due to increased experimental materials and operational costs for the ABSL-3 laboratory[30] - Research and development expenses for Q3 2020 amounted to ¥33.95 million, a significant increase of 78.5% from ¥19.04 million in Q3 2019[54] Government Subsidies - The company received government subsidies amounting to CNY 8,140,827.83 for the first nine months[20] Inventory and Receivables - Accounts receivable increased by RMB 208.38 million, a rise of 36.16%, mainly due to increased sales revenue from government procurement of vaccines for foot-and-mouth disease and highly pathogenic avian influenza[24] - Other receivables increased by RMB 21.31 million, up 49.89%, primarily due to increased payments and deposits in the biopharmaceutical sector[24] Changes in Expenses - Cash paid for dividends and interest decreased by RMB 329.98 million, down 83.20%, due to a reduction in cash dividends distributed compared to the previous year[32] - The company’s sales expenses for Q3 2020 were ¥89.68 million, an increase of 97.1% from ¥45.43 million in Q3 2019[54] - The company’s management expenses for Q3 2020 were ¥30.45 million, slightly up from ¥28.52 million in Q3 2019[54]